BioSpace News Archive

Drug Development

AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer’s Disease-like Symptoms in Subjects with Down Syndrome

Anti-Abeta vaccine demonstrates strong safety and preliminary immunogenicity results in subjects with Down syndrome

July 11, 2019
·
9 min read
Policy

White House Kills Drug Rebate Proposal After ‘Careful Analysis and Thorough Consideration’

Some members of the Trump administration worried that passing the rebates directly to consumers would cost the federal government too much in the long run.

July 11, 2019
·
2 min read
·
Alex Keown
Drug Development

Biohaven’s Rimegepant for Migraines Heads to the FDA for Approval Following Successful Trial

The co-primary endpoints were pain freedom and freedom from the symptom that bothers the patient the most at two hours after receiving the drug. The trial hit its co-primary endpoints.

July 11, 2019
·
3 min read
·
Mark Terry
Research Roundup: New Test for Autism and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

July 11, 2019
·
4 min read
·
Mark Terry
New Insights into the Vagus Nerve Could Change the Way Diabetes is Treated

A team of researchers finally learned how the vagus nerve transmits its signals, which could have implications in revealing a new way to measure blood glucose levels in people.

July 11, 2019
·
2 min read
·
Alex Keown
Policy

Reckitt Benckiser Settles Indivior Opioid Investigation for $1.4 Billion

Reckitt Benckiser spun Indivior off into a standalone company in 2014. Earlier this year the Department of Justice charged Indivior for its role in the opioid crisis.

July 11, 2019
·
2 min read
·
Alex Keown
Business

Clover Therapeutics Launches With Eye on Age-Related Ocular Diseases

Clover Therapeutics, which sprung out of Clover Health, is supported by a number of biotech and pharma veterans, including Pfizer veteran Cheng Zhang, who is heading up therapeutics, and Genentech veteran Marcel van der Brug, who is the chief scientific officer for therapeutics.

July 11, 2019
·
3 min read
·
Alex Keown
Business

After High-Profile NASH Failure, Gilead Resets with Renown IHI to Sequence Patient DNA

Under the terms of the collaboration and license deal, Gilead will fund Renown IHI’s efforts to sequence and analyze the DNA of 15,000 people who have been diagnosed with NASH or nonalcoholic fatty liver disease in addition to a control group of 40,000 people in Nevada.

July 11, 2019
·
2 min read
·
Mark Terry
Policy

WHO Outlines 5-Year International Regulatory Plan to Improve Drug and Medical Product Quality Assurance

The World Health Organization developed a five-year plan to promote regulatory collaboration and reliance around the world and to assist national regulatory authorities in solving related issues.

July 11, 2019
·
3 min read
·
Mark Terry
Partnership created to uncover reasons for frailty in aging populations

Three national research groups and a leading health technology company are teaming together to discover the frailty biomarkers that may shed light on why some people become frail, determine the severity of frailty and what can be done to help avoid the condition.

July 11, 2019
·
6 min read